177 related articles for article (PubMed ID: 27370636)
1. Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma.
Velikanova LI; Shafigullina ZR; Lisitsin AA; Vorokhobina NV; Grigoryan K; Kukhianidze EA; Strelnikova EG; Krivokhizhina NS; Krasnov LM; Fedorov EA; Sablin IV; Moskvin AL; Bessonova EA
Horm Cancer; 2016 Dec; 7(5-6):327-335. PubMed ID: 27370636
[TBL] [Abstract][Full Text] [Related]
2. High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine Steroid Profiling in the Diagnosis of Adrenal Disorders.
Hines JM; Bancos I; Bancos C; Singh RD; Avula AV; Young WF; Grebe SK; Singh RJ
Clin Chem; 2017 Dec; 63(12):1824-1835. PubMed ID: 28814383
[TBL] [Abstract][Full Text] [Related]
3. Use of urinary steroid profiling for diagnosing and monitoring adrenocortical tumours.
Tiu SC; Chan AO; Taylor NF; Lee CY; Loung PY; Choi CH; Shek CC
Hong Kong Med J; 2009 Dec; 15(6):463-70. PubMed ID: 19966352
[TBL] [Abstract][Full Text] [Related]
4. Gas Chromatography-Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing's Syndrome.
Velikanova LI; Shafigullina ZR; Vorokhobina NV; Malevanaya EV
Bull Exp Biol Med; 2019 Sep; 167(5):676-680. PubMed ID: 31630306
[TBL] [Abstract][Full Text] [Related]
5. Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors.
Vogg N; Müller T; Floren A; Dandekar T; Riester A; Dischinger U; Kurlbaum M; Kroiss M; Fassnacht M
Clin Chim Acta; 2023 Mar; 543():117301. PubMed ID: 36948238
[TBL] [Abstract][Full Text] [Related]
6. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
Arlt W; Biehl M; Taylor AE; Hahner S; Libé R; Hughes BA; Schneider P; Smith DJ; Stiekema H; Krone N; Porfiri E; Opocher G; Bertherat J; Mantero F; Allolio B; Terzolo M; Nightingale P; Shackleton CH; Bertagna X; Fassnacht M; Stewart PM
J Clin Endocrinol Metab; 2011 Dec; 96(12):3775-84. PubMed ID: 21917861
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma.
Kouyama R; Hiraishi K; Sugiyama T; Izumiyama H; Yoshimoto T; Akashi T; Kihara K; Homma K; Shibata H; Hirata Y
Endocr J; 2011; 58(7):527-34. PubMed ID: 21521927
[TBL] [Abstract][Full Text] [Related]
8. Urinary steroid profile in adrenocortical tumors.
Kikuchi E; Yanaihara H; Nakashima J; Homma K; Ohigashi T; Asakura H; Tachibana M; Shibata H; Saruta T; Murai M
Biomed Pharmacother; 2000 Jun; 54 Suppl 1():194s-197s. PubMed ID: 10915023
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors.
Kerkhofs TM; Kerstens MN; Kema IP; Willems TP; Haak HR
Horm Cancer; 2015 Aug; 6(4):168-75. PubMed ID: 25985881
[TBL] [Abstract][Full Text] [Related]
10. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma.
Chortis V; Bancos I; Nijman T; Gilligan LC; Taylor AE; Ronchi CL; O'Reilly MW; Schreiner J; Asia M; Riester A; Perotti P; Libé R; Quinkler M; Canu L; Paiva I; Bugalho MJ; Kastelan D; Dennedy MC; Sherlock M; Ambroziak U; Vassiliadi D; Bertherat J; Beuschlein F; Fassnacht M; Deeks JJ; Biehl M; Arlt W
J Clin Endocrinol Metab; 2020 Mar; 105(3):e307-18. PubMed ID: 31665449
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical adenomas with regression and myelolipomatous changes: urinary steroid profiling supports a distinctive benign neoplasm.
Perna V; Taylor NF; Dworakowska D; Schulte KM; Aylwin S; Al-Hashimi F; Diaz-Cano SJ
Clin Endocrinol (Oxf); 2014 Sep; 81(3):343-9. PubMed ID: 24712713
[TBL] [Abstract][Full Text] [Related]
12. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma.
Gröndal S; Eriksson B; Hagenäs L; Werner S; Curstedt T
Acta Endocrinol (Copenh); 1990 May; 122(5):656-63. PubMed ID: 2141212
[TBL] [Abstract][Full Text] [Related]
13. [The combination of classical tests and methods of chromatography for laboratory diagnostics of cushing's syndrome of different genesis.].
Shafigullina ZR; Velikanova LI; Vorokhobina NV; Malevanaya EV; Strelnikova EG; Pal'cman ZV
Klin Lab Diagn; 2020 Jun; 65(7):418-423. PubMed ID: 32762179
[TBL] [Abstract][Full Text] [Related]
14. Delineating endogenous Cushing's syndrome by GC-MS urinary steroid metabotyping.
Braun LT; Osswald A; Zopp S; Rubinstein G; Vogel F; Riester A; Honegger J; Eisenhofer G; Constantinescu G; Deutschbein T; Quinkler M; Elbelt U; Künzel H; Nowotny HF; Reisch N; Hartmann MF; Beuschlein F; Pons-Kühnemann J; Reincke M; Wudy SA
EBioMedicine; 2024 Jan; 99():104907. PubMed ID: 38128413
[TBL] [Abstract][Full Text] [Related]
15. Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma.
Schweitzer S; Kunz M; Kurlbaum M; Vey J; Kendl S; Deutschbein T; Hahner S; Fassnacht M; Dandekar T; Kroiss M
Eur J Endocrinol; 2019 Feb; 180(2):117-125. PubMed ID: 30481155
[TBL] [Abstract][Full Text] [Related]
16. Serum steroid profiling by mass spectrometry in adrenocortical tumors: diagnostic implications.
Fanelli F; Di Dalmazi G
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):160-165. PubMed ID: 30893084
[TBL] [Abstract][Full Text] [Related]
17. A 13-Steroid Serum Panel Based on LC-MS/MS: Use in Detection of Adrenocortical Carcinoma.
Taylor DR; Ghataore L; Couchman L; Vincent RP; Whitelaw B; Lewis D; Diaz-Cano S; Galata G; Schulte KM; Aylwin S; Taylor NF
Clin Chem; 2017 Dec; 63(12):1836-1846. PubMed ID: 28904054
[TBL] [Abstract][Full Text] [Related]
18. Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma.
Suzuki S; Minamidate T; Shiga A; Ruike Y; Ishiwata K; Naito K; Ishida A; Deguchi H; Fujimoto M; Koide H; Tatsuno I; Ikeda JI; Yamazaki Y; Sasano H; Yokote K
BMC Endocr Disord; 2020 Nov; 20(1):173. PubMed ID: 33228607
[TBL] [Abstract][Full Text] [Related]
19. Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes.
Zheng GY; Zhang XB; Li HZ; Zhang YS; Deng JH; Wu XC
Biochem Genet; 2021 Aug; 59(4):902-918. PubMed ID: 33564960
[TBL] [Abstract][Full Text] [Related]
20. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
